At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity (ROP): A Pilot, Randomized and Prospective Study.
In Brief
A Phase 2 clinical trial evaluating propranolol and sucrose 5% for Retinopathy of Prematurity. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
In premature infants, propranolol (Prop) treatment might suppress continuing neo-vascularization (NV) and decelerate the progression of retinopathy of prematurity (ROP) towards its severe stages (III-V), thus avoiding the need of interventions (CRYO and/or LASER photo-coagulation of the ischemic retina and preventing severe ocular sequelae. We therefore plan to prospectively investigate the influence of prop versus placebo in VLBW infants with ROP stage 1 (zone I), with stage 2 or higher (any zone) or with Plus disease, along with close follow up regarding safety of prop administration and its effect on ROP.
Study Details
Timeline
Interventions
2 mg per kg per day divided in 3 doses for 2-4 weeks
2 ml per Kg per day divided in 3 doses for 2-4 weeks